Joelle L. Burgess

Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2

Sharad K. Verma, Xinrong Tian, Louis V. LaFrance et al. · ACS Medicinal Chemistry Letters · 2012 · 373 citations · Full text

Histone Modifications, Drug Discovery Program, Engineering +18

Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin

Steven D. Knight, Nicholas D. Adams, Joelle L. Burgess et al. · ACS Medicinal Chemistry Letters · 2010 · 367 citations · Full text

Highly Potent Inhibitor, Tumor Biology, Mammalian Target +16

Identification of Novel Inhibitors of the Transforming Growth Factor β1 (TGF-β1) Type 1 Receptor (ALK5)

James F. Callahan, Joelle L. Burgess, James A. Fornwald et al. · Journal of Medicinal Chemistry · 2002 · 309 citations · Full text

Drug Target, Pharmacotherapy, Cell Growth +18

Discovery of GSK1070916, a Potent and Selective Inhibitor of Aurora B/C Kinase

Nicholas D. Adams, Jerry L. Adams, Joelle L. Burgess et al. · Journal of Medicinal Chemistry · 2010 · 108 citations · Full text

Aurora B/c Kinase, Chemoprevention Strategy, Molecular Biology +21

Direct design of a potent non-peptide fibrinogen receptor antagonist based on the structure and conformation of a highly constrained cyclic RGD peptide

Thomas W. Ku, Fadia E. Ali, Linda S. Barton et al. · Journal of the American Chemical Society · 1993 · 90 citations

Peptide Engineering, Altmetric Attention Score, Peptide Science +22